Clinical Trial Update: MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing MK0991 to Amphotericin B for empirical therapy in febrile neutropenic pediatric patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Febrile Neutropenia
• Neutropenia

Drugs mentioned

• Amphotericin B (Amphotericin B)
• MK0991

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neutropenia, Fever | Phase 2 | Status: COMPLETED